Novocure (NASDAQ: NVCR) reported Q1 EPS of ($0.62), $0.13 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $174.1 million versus the consensus estimate of $167.77 million.

GUIDANCE:

Novocure sees FY2026 revenue of $690-710 million, versus the consensus of $694.7 million.

For earnings history and earnings-related data on Novocure (NVCR) click here.